Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Ametek
AME
$59.3B
| $21M | 0.02% |
210,650
-317,300
| -60% | -$30.1M |
|
|
MOBL
977
DELISTED
MobileIron, Inc.
MOBL
| $21M | 0.02% |
4,314,645
-140,495
| -3% | -$748K |
|
978
TransAlta
TAC
$3.92B
| $21M | 0.02% |
2,928,279
+1,067,638
| +57% | +$6.93M |
|
979
KRONOS Worldwide
KRO
$905M
| $20.9M | 0.02% |
1,561,900
+167,200
| +12% | +$2.19M |
|
980
Coty
COTY
$2.43B
| $20.8M | 0.02% |
1,852,568
+1,302,968
| +237% | +$14.8M |
|
981
Benchmark Electronics
BHE
$2.94B
| $20.8M | 0.02% |
606,300
+53,000
| +10% | +$1.75M |
|
982
Phibro Animal Health
PAHC
$1.37B
| $20.8M | 0.02% |
838,500
+44,000
| +6% | +$1.02M |
|
|
HUD
983
DELISTED
Hudson Ltd. Class A Common Shares
HUD
| $20.7M | 0.02% |
1,352,608
+351,000
| +35% | +$4.58M |
|
|
QVCGA
984
DELISTED
QVC Group Inc Series A
QVCGA
| $20.7M | 0.02% |
+50,506
| New | +$22.8M |
|
985
Northwest Bancshares
NWBI
$2.31B
| $20.7M | 0.02% |
1,242,382
-499,193
| -29% | -$8.34M |
|
986
Federal Agricultural Mortgage
AGM
$2.58B
| $20.6M | 0.02% |
246,700
-7,400
| -3% | -$615K |
|
987
Coca-Cola Europacific Partners
CCEP
$47.3B
| $20.6M | 0.02% |
405,738
+373,413
| +1,155% | +$19.7M |
|
988
Rush Enterprises Class A
RUSHA
$9.41B
| $20.6M | 0.02% |
994,707
-549,419
| -36% | -$10.7M |
|
|
AXE
989
DELISTED
Anixter International Inc
AXE
| $20.5M | 0.02% |
222,800
+136,000
| +157% | +$11M |
|
|
MNDT
990
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $20.4M | 0.02% |
1,234,000
-378,300
| -23% | -$6.07M |
|
|
SEM
991
DELISTED
Select Medical
SEM
| $20.4M | 0.02% |
1,621,587
+1,170,950
| +260% | +$12.6M |
|
|
PARAA
992
DELISTED
Paramount Global Class A
PARAA
| $20.4M | 0.02% |
454,425
+130,138
| +40% | +$5.51M |
|
993
Great Southern Bancorp
GSBC
$877M
| $20.4M | 0.02% |
321,500
+42,800
| +15% | +$2.59M |
|
994
Lumen
LUMN
$6.6B
| $20.3M | 0.02% |
1,540,257
+565,500
| +58% | +$7.58M |
|
995
United States Lime & Minerals
USLM
$3.42B
| $20.3M | 0.02% |
1,125,705
-4,095
| -0.4% | -$71.9K |
|
|
NGD
996
DELISTED
New Gold Inc
NGD
| $20.3M | 0.02% |
23,058,954
+1,101,772
| +5% | +$997K |
|
997
Hackett Group
HCKT
$278M
| $20.2M | 0.02% |
1,252,444
+132,114
| +12% | +$2.1M |
|
998
Cirrus Logic
CRUS
$6.11B
| $20.2M | 0.02% |
245,220
+71,700
| +41% | +$4.86M |
|
999
American Water Works
AWK
$26.8B
| $20.2M | 0.02% |
164,400
+119,400
| +265% | +$14.5M |
|
1000
Bilibili
BILI
$7.14B
| $20.2M | 0.02% |
1,084,350
+544,650
| +101% | +$8.84M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.